Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.46 |
| ▸ | PDE4A | P27815 | 12/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17243619 | 0.92 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4CKCNH2 | |
| SCHEMBL17243639 | 0.90 | NPC1 (0.49) | PDE4BPDE4DPDE4APDE4CKCNH2 | |
| SCHEMBL17233512 | 0.86 | KCNH2 (0.54) | PDE4BPDE4DPDE4APDE4CKCNH2 | |
| SCHEMBL17243928 | 0.86 | PDE4B (0.61) | PDE4BPDE4DPDE4APDE4CKCNH2 | |
| SCHEMBL17233517 | 0.80 | PDE4A (0.51) | PDE4BPDE4DPDE4APDE4CKCNH2 | |
| SCHEMBL17243620 | 0.80 | PDE4A (0.54) | PDE4BPDE4DPDE4APDE4CKCNH2 | |
| SCHEMBL17243615 | 0.79 | PDE4A (0.53) | PDE4BPDE4DPDE4APDE4CKCNH2 | |
| SCHEMBL17243624 | 0.79 | PDE4A (0.53) | PDE4BPDE4DPDE4APDE4CKCNH2 | |
| SCHEMBL17233514 | 0.79 | KCNH2 (0.73) | PDE4BPDE4DPDE4APDE4CKCNH2 | |
| SCHEMBL17243638 | 0.79 | KCNH2 (0.59) | PDE4BPDE4DPDE4APDE4CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181244-B1 | Substituted pyrido[2,3-c]pyridazin-4(1H)-ones as tumor necrosis factor alpha and phosphodiesterase 4 inhibitors | Xuanzhu Pharma Co., Ltd. (CN) | 2015-11-10 | — | — | US | disclosed |